Daniel Taylor of the Wharton School said it’s rare for corporate executives to cash out their stocks prior to releasing a highly anticipated product, as the CEOs of Pfizer and Moderna did last month. “They’re selling a vaccine that people are already skeptical of,” Taylor said. “There is a point when the actions of the executives will affect what people think of the vaccines themselves.”